Literature DB >> 24117452

Unusual adverse choroidal reaction to intravitreal bevacizumab in aggressive posterior retinopathy of prematurity: the Indian Twin Cities ROP screening (ITCROPS) data base report number 7.

Jay Chhablani1, Padmaja Kumari Rani, Divya Balakrishnan, Subhadra Jalali.   

Abstract

PURPOSE: To describe a case of choroidal ischemia in a neonate after single, bilateral, intravitreal bevacizumab (IVB) injection for severe zone 1 aggressive posterior retinopathy of prematurity (AP-ROP).
METHODS: A six-week-old baby, born at a gestation age of 28 weeks and birth weight of 1.08 kg, presented at a postconceptional age of 34 weeks for ROP screening. On examination, both eyes revealed engorged iris new vessels with poorly dilating pupils. Retinal examination showed media haze, severe zone 1 APROP with confluent new vessels, severe plus disease, and early vitreous condensation at the edge of new vessels for 12 clock hours. The child was treated bilaterally, with single IVB injection before laser. After 16 hours, hypotony and exudative retinal detachment with patches of choroidal whitening suggestive of choroidal ischemia were seen.
RESULTS: The child was treated with topical steroids and cycloplegic drops and exudative retinal detachment resolved on the tenth day. Initial resolution of new vessels showed recurrence after two weeks and was treated with laser photocoagulation. Stable retinopathy status was noted up to six months follow-up.
CONCLUSION: Choroidal ischemia secondary to a single IVB injection for the treatment of AP-ROP could be an unusual complication which raises the concern of its use as a monotherapy in neonates.

Entities:  

Keywords:  APROP; ROP; choroidal ischemia; intravitreal bevacizumab

Mesh:

Substances:

Year:  2013        PMID: 24117452     DOI: 10.3109/08820538.2013.835842

Source DB:  PubMed          Journal:  Semin Ophthalmol        ISSN: 0882-0538            Impact factor:   1.975


  6 in total

1.  Serial evaluation of retinal vascular changes in infants treated with intravitreal bevacizumab for aggressive posterior retinopathy of prematurity in zone I.

Authors:  T R Padhi; T Das; S Rath; L Pradhan; S Sutar; K G Panda; R Modi; S Jalali
Journal:  Eye (Lond)       Date:  2015-11-20       Impact factor: 3.775

Review 2.  Pharmacologic interventions for the prevention and treatment of retinopathy of prematurity.

Authors:  Kay D Beharry; Gloria B Valencia; Douglas R Lazzaro; Jacob V Aranda
Journal:  Semin Perinatol       Date:  2016-01-29       Impact factor: 3.300

3.  Prospective clinical study of two different treatment regimens of combined laser photocoagulation and intravitreal bevacizumab for retinopathy of prematurity: the Indian Twin Cities ROP Study (ITCROPS) database report number 9.

Authors:  Venkateshnaidu Laveti; Divya Balakrishnan; Padmaja Kumari Rani; Ashik Mohamed; Subhadra Jalali
Journal:  Int Ophthalmol       Date:  2020-08-10       Impact factor: 2.031

Review 4.  A Systematic Review and Meta-Analysis on the Safety of Vascular Endothelial Growth Factor (VEGF) Inhibitors for the Treatment of Retinopathy of Prematurity.

Authors:  Laura Pertl; Gernot Steinwender; Christoph Mayer; Silke Hausberger; Eva-Maria Pöschl; Werner Wackernagel; Andreas Wedrich; Yosuf El-Shabrawi; Anton Haas
Journal:  PLoS One       Date:  2015-06-17       Impact factor: 3.240

5.  Enteral Arg-Gln Dipeptide Administration Increases Retinal Docosahexaenoic Acid and Neuroprotectin D1 in a Murine Model of Retinopathy of Prematurity.

Authors:  Lynn Calvin Shaw; Sergio Li Calzi; Nan Li; Leni Moldovan; Nilanjana Sengupta-Caballero; Judith Lindsey Quigley; Mircea Ivan; Bokkyoo Jun; Nicolas G Bazan; Michael Edwin Boulton; Julia Busik; Josef Neu; Maria B Grant
Journal:  Invest Ophthalmol Vis Sci       Date:  2018-02-01       Impact factor: 4.799

6.  Ocular complications following intravitreal bevacizumab injection for retinopathy of prematurity and assessment of risk factors.

Authors:  Fatemeh Bazvand; Hamid Riazi-Esfahani; Ahmad Mirshahi; Alireza Khodabande; Hasan Khojastheh; Afsar Dastjani Farahani; Ramak Roohipourmoallai; Marjan Imani; Hooshang Faghihi; Nazanin Ebrahimi Adib; Mohammadreza Mehrabi Bahar
Journal:  Int J Retina Vitreous       Date:  2021-01-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.